Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.95 SEK | +1.53% | +14.75% | +57.96% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+57.96% | 181M | C+ | ||
+9.42% | 114B | B+ | ||
+11.84% | 104B | B+ | ||
-14.15% | 22.41B | B+ | ||
-1.05% | 22.28B | B | ||
-5.29% | 19.07B | A- | ||
-38.29% | 18B | A- | ||
-4.16% | 17.89B | B | ||
+7.99% | 14.28B | C+ | ||
+36.24% | 12.55B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BINV Stock
- Ratings BioInvent International AB